Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Related Posts
Fung CH, Mak S, Ash G, Der-McLeod E, Ereso J, Naeem S, Liu J, Ghadimi S, Te TT, Chan V, Hurtado J, Wong S, Zeidler[...]
Kawai K, Muhere CF, Lemos EV, Francis JM. Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2025 Oct[...]
Nguyen KL, Loke YH, Li JM, Bedayat A, Yang HJ, Xie Y, Christodoulou AG, Li D, Zhong X, Finn JP. Ferumoxytol-Enhanced Cardiovascular Magnetic Resonance Imaging:[...]